Fundraising FoxVaxxas
3 known investors
Find your way into Vaxxas
Sign up to see every warm intro you have to Vaxxas
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vaxxas team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Biotechnology company enhancing vaccine performance with its HD-MAP high-density microarray skin-delivery platform, targeting infectious disease and oncology.
Investors · 3
OneVentureslisted by OneVenturesSydney · $3.3M – $13.2M
How we know: OneVentures's portfolio page · funding news · the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements$23M disclosed across 1 of 3 rounds · 2022–2025
- $23MraisedDec 2022 · 2 sources
Brandon Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Related companies · 7
VaccinexVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
DynavaxDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
VaxcyteVaxcyte is a clinical-stage biotechnology company developing vaccines to prevent or treat bacterial infectious diseases, including pneumococcal conjugate vaccine candidates. Founded in 2013, it uses a cell-free protein synthesis platform to engineer vaccines for children and adults.
AbivaxAbivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
VaxCareVaxCare operates a platform that automates procurement, inventory management, patient eligibility, charting, and billing for vaccines and contraceptives at medical practices. It serves health systems, pediatric, family medicine, OB-GYN, and internal medicine practices, connecting suppliers, EHRs, and payers to keep practices stocked with ACIP-recommended vaccines and contraceptives.
CentivaxCentivax is a biotechnology company developing broad-spectrum vaccines, including a universal influenza vaccine.
ImvaxImvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
Companies working in the same space as Vaxxas.
Frequently asked questions
- What does Vaxxas do?
- Biotechnology company enhancing vaccine performance with its HD-MAP high-density microarray skin-delivery platform, targeting infectious disease and oncology.
- Who are Vaxxas's investors?
- Vaxxas's investors include OneVentures, R&D Tax Incentive, Torrey Pines Investment.
- How much funding has Vaxxas raised?
- Vaxxas has disclosed $23M raised across 1 of its 3 known rounds.